Related Experiment Videos
Functional knock-out of c-myb by an intracellular anti-c-Myb single-chain antibody
1Gene Therapy Program, University of Alabama at Birmingham, 1824 6th Avenue South, WTI620, Birmingham, Alabama, 35294, USA.
Abstract:
Aberrant expression of the c-myb proto-oncogene is a key factor in the development of the neoplastic phenotype in a variety of contexts. On this basis, it has been proposed that ablation of c-myb function might be an effective approach for therapy. To this end, we have employed an intracellular single-chain antibody (sFv) approach to achieve the functional knock-out of the c-Myb onco-protein. We derived an anti-c-Myb sFv, which was configured into eukaryotic expression plasmids. We confirmed the expression of the cytoplasmic and nuclear forms of the sFvs in the correct subcellular compartments by immunofluorescent staining. Importantly, the anti-c-Myb sFvs strongly inhibited the transactivation activity of c-Myb. Furthermore, cytotoxic effect of the sFv was observed only in the c-Myb positive cell line K562. These results suggest that anti-c-Myb sFv is a valuable tool for understanding the molecular mechanisms of c-myb induced transformation. In addition, this approach may have potential utility in the gene therapy for c-myb-dependent malignant diseases.
Insights
Researchers developed an anti-c-Myb single-chain variable fragment (sFv) to inhibit the c-Myb oncoprotein. This approach shows potential for gene therapy in c-myb-dependent cancers.
Area of Science:
- Molecular Biology
- Oncology
- Gene Therapy
Background:
- Aberrant expression of the c-myb proto-oncogene is implicated in neoplastic phenotype development.
- Targeting c-myb function is a proposed therapeutic strategy for cancer.
- Intracellular antibodies (single-chain variable fragments, sFvs) offer a method for functional protein knockout.
Purpose of the Study:
- To develop an intracellular single-chain antibody (sFv) for functional ablation of the c-Myb oncoprotein.
- To assess the efficacy of anti-c-Myb sFv in inhibiting c-Myb activity and inducing cytotoxicity in cancer cells.
Main Methods:
- Derived an anti-c-Myb sFv and engineered eukaryotic expression plasmids.
- Confirmed sFv expression in correct subcellular compartments using immunofluorescent staining.
- Assessed the impact of sFv on c-Myb transactivation activity and evaluated cytotoxicity in K562 cells.
Main Results:
- Successfully expressed anti-c-Myb sFvs in both cytoplasmic and nuclear compartments.
- Demonstrated significant inhibition of c-Myb transactivation activity by the anti-c-Myb sFvs.
- Observed a cytotoxic effect specifically in the c-Myb-positive K562 cell line.
Conclusions:
- Anti-c-Myb sFv is a potent tool for investigating c-myb's role in cellular transformation.
- This approach holds promise for developing gene therapies targeting c-myb-dependent malignancies.
- Intracellular antibody technology provides a viable strategy for oncoprotein functional knockout.